Get started
BRISTOL-MYERS SQUIBB COBRISTOL-MYERS SQUIBB COBRISTOL-MYERS SQUIBB CO

BRISTOL-MYERS SQUIBB CO

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

BMY trade ideas

$BMY Bristol Myers trade level The stock is on a bullish trajectory towards resistance at $64.60 but is lacking in volume and needs a little rotation to take place. Still trading at a very reasonable 17 P/E ratio. Yield attractive at 3%. Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
NYSE:BMYLong
by RedHotStocks
$BMY beats but needs a pullback for entry. Bristol-Myers Squibb (NYSE:BMY) Q3 results: Revenues: $6,007M (+5.6%); product sales: $5,768M (+6.2%). Key product sales: Eliquis: $1,928M (+22.3%); Opdivo: $1,817M (+1.3%); Orencia: $767M (+13.6%); Sprycel: $558M (+13.6%); Yervoy: $353M (-7.6%). Net income: $1,366M (-28.6%); EPS: $0.83 (-28.4%); non-GAAP EPS: $1.17 (+7.3%). 2019 guidance: EPS: $3.46 - 3.56 from $3.73 - 3.83; non-GAAP EPS: $4.25 - 4.35 from $4.20 - 4.30. Source seeking Alpha Possible entry level $54-$57 with $63 as target and strong resistance. P/E ratio 14.94 - undervalued. Short interest high at 9.16%. Company profile Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
NYSE:BMYLong
by Bullishcharts
Nice Long For Earnings""For Bristol-Myers, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +0.38%. On the other hand, the stock currently carries a Zacks Rank of #3. So, this combination indicates that Bristol-Myers will most likely beat the consensus EPS estimate.....For the last reported quarter, it was expected that Bristol-Myers would post earnings of $1.06 per share when it actually produced earnings of $1.18, delivering a surprise of +11.32%.Over the last four quarters, the company has beaten consensus EPS estimates four times." (Zacks)
NYSE:BMYLong
by Ron-V
$BMY Bullish break imminent in Bristol-MyersTrading at a very low 13.77 P/E ratio. Short interest is quiet high at 9.15%, which could ignite a rally. Bristol-Myers Squibb resumed with Buy rating and $60 (16% upside) price target at BofAML. Company profile Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
NYSE:BMY
by RedHotStocks
BMY offers short term gains.We are of the opinion that the recent resistance level @ $54 looks on the near term horizon, momentum has been strong, but volume is on the decline. Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
NYSE:BMYLong
by Bullishcharts